Total Payments
$5,205
2024 Payments
$2,412
Companies
22
Transactions
159
Medicare Patients
869
Medicare Billing
$490,021
Payment Breakdown by Category
Food & Beverage$4,346 (83.5%)
Travel$859.12 (16.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,346 | 157 | 83.5% |
| Travel and Lodging | $859.12 | 2 | 16.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neuronetics, Inc. | $1,460 | 2 | $0 (2024) |
| ABBVIE INC. | $948.85 | 49 | $0 (2024) |
| Indivior Inc. | $632.09 | 25 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $423.69 | 9 | $0 (2024) |
| Allergan, Inc. | $256.86 | 9 | $0 (2020) |
| Braeburn Inc. | $163.09 | 9 | $0 (2024) |
| Novo Nordisk Inc | $160.94 | 10 | $0 (2020) |
| Covidien LP | $146.00 | 1 | $0 (2018) |
| Boston Scientific Corporation | $141.47 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $135.90 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,412 | 41 | Neuronetics, Inc. ($1,460) |
| 2023 | $283.90 | 19 | ABBVIE INC. ($248.60) |
| 2022 | $339.19 | 12 | ABBVIE INC. ($281.50) |
| 2021 | $233.74 | 11 | AbbVie Inc. ($151.58) |
| 2020 | $122.57 | 7 | Indivior Inc. ($64.70) |
| 2019 | $467.80 | 13 | Indivior Inc. ($205.03) |
| 2018 | $645.63 | 18 | Otsuka America Pharmaceutical, Inc. ($191.45) |
| 2017 | $700.43 | 38 | Otsuka America Pharmaceutical, Inc. ($129.84) |
All Payment Transactions
159 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $3.03 | General |
| Category: Opioid Use Disorder | ||||||
| 11/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.29 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $15.79 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/15/2024 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $746.71 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 11/15/2024 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Travel and Lodging | Cash or cash equivalent | $713.12 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.60 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Opioid Use Disorder | ||||||
| 10/28/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: OUD | ||||||
| 10/27/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $141.47 | General |
| Category: General - Vascular Access_IC | ||||||
| 10/24/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | Cash or cash equivalent | $105.98 | General |
| Category: Opioid Use Disorder | ||||||
| 10/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 10/09/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $3.63 | General |
| Category: Opioid Use Disorder | ||||||
| 10/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $102.40 | General |
| Category: PSYCHIATRY | ||||||
| 09/17/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: OUD | ||||||
| 09/12/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $4.53 | General |
| Category: Opioid Use Disorder | ||||||
| 08/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: VIROLOGY | ||||||
| 08/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $36.41 | General |
| Category: OUD | ||||||
| 07/09/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: Opioid Use Disorder | ||||||
| 07/09/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $3.71 | General |
| Category: Opioid Use Disorder | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 54 | 440 | $34,460 | $24,830 |
| 2022 | 7 | 172 | 989 | $79,100 | $56,085 |
| 2021 | 6 | 216 | 2,172 | $285,159 | $159,741 |
| 2020 | 10 | 427 | 3,337 | $587,037 | $249,365 |
Total Patients
869
Total Services
6,938
Medicare Billing
$490,021
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 22 | 328 | $24,600 | $16,984 | 69.0% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 21 | 92 | $7,360 | $5,603 | 76.1% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 11 | 20 | $2,500 | $2,243 | 89.7% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 33 | 443 | $33,225 | $20,792 | 62.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 32 | 224 | $17,920 | $13,859 | 77.3% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 24 | 60 | $7,500 | $6,828 | 91.0% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 25 | 30 | $6,300 | $5,948 | 94.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 86 | $6,020 | $3,495 | 58.1% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 11 | 17 | $2,975 | $2,656 | 89.3% |
| 90853 | Group psychotherapy | Office | 2022 | 19 | 129 | $5,160 | $2,507 | 48.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 40 | 660 | $84,650 | $41,012 | 48.4% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 38 | 183 | $49,630 | $36,369 | 73.3% |
| 90832 | Psychotherapy, 30 minutes | Office | 2021 | 38 | 616 | $59,955 | $26,534 | 44.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 465 | $36,974 | $22,218 | 60.1% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 37 | 124 | $33,575 | $19,417 | 57.8% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 25 | 124 | $20,375 | $14,189 | 69.6% |
| 80307 | Testing for presence of drug | Office | 2020 | 50 | 957 | $191,400 | $59,100 | 30.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 51 | 996 | $83,664 | $51,696 | 61.8% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 46 | 193 | $73,750 | $38,321 | 52.0% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 47 | 128 | $51,200 | $31,428 | 61.4% |
| 90832 | Psychotherapy, 30 minutes | Office | 2020 | 43 | 539 | $77,770 | $28,768 | 37.0% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 37 | 158 | $59,600 | $17,943 | 30.1% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 38 | 67 | $26,500 | $10,291 | 38.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 66 | $8,448 | $4,632 | 54.8% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 36 | 83 | $7,205 | $4,573 | 63.5% |
About Dr. Manish Parikh, MD
Dr. Manish Parikh, MD is a Psychiatry healthcare provider based in Ashland, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457390791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manish Parikh, MD has received a total of $5,205 in payments from pharmaceutical and medical device companies, with $2,412 received in 2024. These payments were reported across 159 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($4,346).
As a Medicare-enrolled provider, Parikh has provided services to 869 Medicare beneficiaries, totaling 6,938 services with total Medicare billing of $490,021. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Ashland, KY
- Active Since 06/05/2006
- Last Updated 01/28/2026
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1457390791
Products in Payments
- NEUROSTAR TMS THERAPY SYSTEM (Device) $1,460
- VRAYLAR (Drug) $1,114
- SUBLOCADE (Drug) $562.62
- ABILIFY MAINTENA (Drug) $289.59
- BRIXADI (Drug) $163.09
- REXULTI (Drug) $134.10
- BELSOMRA (Drug) $107.48
- Epclusa (Drug) $89.60
- Zubsolv (Drug) $86.52
- PRADAXA (Drug) $82.54
- Saxenda (Drug) $68.52
- reSET-O (Device) $57.97
- LATUDA (Drug) $56.44
- SUBOXONE SUBLINGUAL FILM (Drug) $56.08
- Aristada 441 mg (Drug) $51.35
- MAVYRET (Drug) $37.86
- BYSTOLIC (Drug) $35.35
- INVEGA SUSTENNA (Drug) $34.16
- HYSINGLA ER (Drug) $33.82
- Probuphine (Drug) $29.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Ashland
Scott Lance, M.d, M.D
Psychiatry — Payments: $10,543
Psychiatry $10,543
Frances Swarn, M.d, M.D
Psychiatry — Payments: $2,592
Psychiatry $2,592
Anne Zappacosta, Md, MD
Psychiatry — Payments: $1,784
Psychiatry $1,784
Brittany Richardson, Do, DO
Psychiatry — Payments: $1,316
Psychiatry $1,316
Amber Wireman, Do, DO
Psychiatry — Payments: $1,193
Psychiatry $1,193
Veronika Logovinsky, M.d, M.D
Psychiatry — Payments: $880.92
Psychiatry $880.92